Evidence reviewed: September 2026.
VITARAN is an established name within the professional polynucleotide category, but choosing between presentations requires more than comparing syringe size. This Longeva Pharma guide focuses specifically on the VITARAN range: formulation, VITARAN I versus VITARAN II, treatment-area positioning, clinical evidence, safety considerations and professional product selection.
Which VITARAN do I need?
Periorbital-focused presentation: View VITARAN I 1ml
Larger treatment areas: View VITARAN II 2ml
Comparing the wider category: Explore professional polynucleotides
VITARAN at a Glance
The official VITARAN documentation supplied to Longeva describes VITARAN as a CE-marked polynucleotide injectable containing 20 mg/ml polynucleotide (PN 2%). It identifies the DNA source as trout DNA and positions the product around skin rejuvenation, regeneration and repair.
| VITARAN I | VITARAN II | |
|---|---|---|
| PN concentration | 20 mg/ml / PN 2% | 20 mg/ml / PN 2% |
| Current Longeva listing | 1 ml × 1 syringe | 2 ml × 1 syringe |
| Primary positioning | Periorbital area | Larger treatment areas |
Key point: the supplied manufacturer material states that VITARAN I and VITARAN II have the same 2% PN concentration. The principal difference is presentation volume and treatment-area positioning, not a stronger versus weaker concentration.
What Is VITARAN?
VITARAN belongs to the professional injectable polynucleotide category. Rather than conventional filler-like projection or structural augmentation, the supplied manufacturer material positions it around skin quality and biostimulation. Practitioners should select products according to the exact presentation, treatment area, patient assessment, current manufacturer information and their own competence.
For broader PN education, read Polynucleotides: What Practitioners Should Understand.
VITARAN I: The Periorbital Presentation
The supplied manufacturer documentation positions VITARAN I for the periorbital area and lists concerns including periocular fine lines and wrinkles, crepey under-eye skin, mild-to-moderate hollows, dark circles, eye bags and puffiness.
Where VITARAN I Fits in a Clinic Portfolio
The smaller presentation may be relevant where a clinic wants a VITARAN option focused on targeted periocular protocols. The 1 ml presentation should not be described as a weaker formulation: the supplied documentation states the same 2% PN concentration for VITARAN I and II.
VITARAN II: The 2 ml Presentation for Larger Areas
The supplied documentation positions VITARAN II for larger treatment areas including the full face, neck, hands, chest, décolletage and selected body areas. The current Longeva Pharma listing is a 2 ml × 1 syringe presentation.
Where VITARAN II Fits in Practice
For clinics offering PN treatment beyond the periocular region, VITARAN II provides the larger-volume VITARAN presentation. Product selection should remain patient- and area-specific.
VITARAN I vs VITARAN II: What's the Difference?
Both are stated in the supplied documentation to contain 20 mg/ml PN (2%). VITARAN I is positioned for the periocular area; VITARAN II is positioned for larger treatment areas. A larger syringe should therefore not be described as a stronger concentration.
SHOP VITARAN & PROFESSIONAL POLYNUCLEOTIDES
What About VITARAN Eyes?
Longeva Pharma currently has a separate product listing titled VITARAN Eyes – Polynucleotide (1x1ml), while the supplied manufacturer document describes VITARAN I as the eye-focused presentation. Practitioners should therefore check the exact SKU, presentation and current supporting documentation rather than treating the names as automatically interchangeable.
For cross-brand periocular product selection, see our Best Under-Eye Polynucleotides: A UK Practitioner Guide.
What Does the Manufacturer State About VITARAN?
The supplied VITARAN material attributes potential effects including increased collagen and elastin production, improved cell regeneration, hydration, tone and texture, improved firmness and elasticity, reduced appearance of fine lines and wrinkles, antioxidant and anti-inflammatory properties, and support for the skin barrier. These are manufacturer-stated benefits, not guaranteed outcomes.
What Does the Clinical Evidence Show?
The supplied material references a study titled Effects of Polynucleotide in the Correction of Crow's Feet Using an Antera Three-Dimensional Camera. It describes 30 healthy volunteers aged 19–60 who underwent four treatments at two-week intervals. The material reports improvement in wrinkles without significant adverse reactions and reports participant satisfaction; it also reports observations relating to pores, texture and skin tone.
How Should Practitioners Interpret This?
The study provides product-relevant evidence but involved a small defined population and a specific periocular protocol. It should not be extrapolated into guaranteed outcomes or evidence that VITARAN is universally superior to another PN formulation.
Study Schedule vs Manufacturer Protocol
The referenced study used four treatments at two-week intervals. Separately, the supplied manufacturer protocol describes 2–3 treatments spaced 3–4 weeks apart and states that optimum results show 2–4 weeks post-treatment. These refer to different contexts and should not be conflated. Practitioners should follow the current documentation for the exact product supplied.
Treatment Technique and Professional Use
The supplied professional material describes cannula and superficial microdroplet approaches. This guide deliberately does not reproduce a step-by-step injection protocol. Product information online is not a substitute for anatomical knowledge, appropriate hands-on training, current manufacturer instructions or individual clinical judgement.
Safety, Contraindications and Patient Selection
The supplied material lists contraindications and cautions including relevant medication use, fish allergy, autoimmune disease, hypersensitivity to sodium polynucleotide, pregnancy or breastfeeding and treatment in patients under 18, among other considerations. Practitioners should consult the complete current product documentation and complete an appropriate patient assessment.
Downtime and Aftercare
The supplied information states that bruising or swelling may remain apparent for up to one week following injection. It also advises avoiding makeup for 12 hours and avoiding sun/UV, cold and heat exposure for up to two weeks. Aftercare should be appropriate to the exact product, treatment area and patient.
VITARAN vs Other Polynucleotides
VITARAN should not automatically be treated as interchangeable with another PN formulation. Products can differ in presentation, intended anatomical positioning and supporting documentation. Rather than duplicating our comparison content here, practitioners can read the under-eye PN comparison or PN vs PDRN vs Exosomes guide.
Choosing VITARAN for Your Clinic
VITARAN I
Consider the smaller, periocular-focused presentation where it corresponds with the patient's assessment and intended treatment plan.
VITARAN II
Consider the larger presentation for broader manufacturer-positioned treatment areas where appropriate.
Stocking Both Presentations
For clinics offering both targeted periocular and broader skin-quality protocols, stocking both presentations can allow product volume to be selected according to treatment area rather than treating the range as two different strengths.
Why Order VITARAN from Longeva Pharma?
Professional injectable purchasing should consider provenance, packaging integrity, batch and expiry traceability, storage requirements and access to current product documentation alongside price. Longeva Pharma provides a professional purchasing pathway for eligible practitioners and a wider polynucleotide collection for clinics comparing their PN stock.
SHOP PROFESSIONAL POLYNUCLEOTIDES
VITARAN Practitioner FAQs
What concentration is VITARAN?
The supplied manufacturer documentation states 20 mg/ml polynucleotide (PN 2%).
Is VITARAN II stronger than VITARAN I?
Not by PN concentration according to the supplied documentation. Both are stated to contain PN 2%; the presentations differ in volume and treatment-area positioning.
Which VITARAN is positioned for the eye area?
The supplied manufacturer documentation positions VITARAN I for the periorbital area.
Which VITARAN is positioned for the face and neck?
The supplied documentation positions VITARAN II for larger areas including the full face and neck.
How many treatments does the supplied VITARAN protocol describe?
It describes 2–3 treatments spaced 3–4 weeks apart. Practitioners should verify the current instructions supplied with the exact product.
Is the research schedule the same as the manufacturer protocol?
No. The study described in the supplied material used four treatments at two-week intervals. That study design should not be conflated with the separate manufacturer protocol.
Where can UK practitioners order VITARAN?
Longeva Pharma currently lists VITARAN products within its professional polynucleotide range.
Order VITARAN from Longeva Pharma
The practical distinction within the supplied range is clear: VITARAN I is the smaller, periocular-focused PN 2% presentation, while VITARAN II is the larger PN 2% presentation positioned for broader treatment areas.
SHOP VITARAN I | SHOP VITARAN II | EXPLORE ALL POLYNUCLEOTIDES
Related Longeva Pharma practitioner resources
Explore Toxins and Diluents; Longeva Pharma on Faces; Greater Manchester same-day toxin supply; toxin product and service directory; Faces Consent practitioner guide; practitioner account registration. Prescription-only medicines require appropriate verification, prescribing and dispensing; same-day availability depends on location, timing and stock.